Page 4 - விரைவுபடுத்து வணிகமயமாக்கல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

What does it take to supply COVID-19 vaccines across the globe? Here s how the leading players are working it

Mar 3, 2021 9:45am COVID-19 vaccine shipments are now underway. Here are the supply chains tasked with producing billions of doses. (nevodka/iStock/Getty Images Plus/Getty Images) As COVID-19 gained steam worldwide last spring, little was known about the disease and the havoc it would wreak on the world. A year later, vaccines offer hope in the fight against the virus, but it will be a monumental task to produce them and deliver them around the planet. That these vaccines were invented, put through clinical testing and either have been rolled out or are nearing distribution is an accomplishment in itself, but the work is really just starting. The companies leading the charge aim to produce billions of doses to vaccinate the world s population, and encouraging real-world data from the ongoing rollouts are showing why it s such an important effort.

United statesUnited kingdomCzech republicRegion flamandeGrand riverMexico generalNew hampshireNorth carolinaUppsala lanWaals gewestSouth africaEstado do rioOswaldo cruzRio grande do sulAlex gorskyStephane bancel

Novavax was on its last leg pre-COVID With a promising shot on deck, it s now eying a big 2021

Novavax was on its last leg pre-COVID With a promising shot on deck, it s now eying a big 2021
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Stan erckSerum instituteSerum institute of indiaUncover rare disease insightsAccelerate commercializationImprove patientஸ்டான் ஏற்க்க்சீரம் நிறுவனம்சீரம் நிறுவனம் ஆஃப் இந்தியாவிரைவுபடுத்து வணிகமயமாக்கல்மேம்படுத்த நோயாளி

CDMO Celonic to beef up cell and gene therapy work at up-and-coming Novartis hub

Mar 3, 2021 12:19pm Novartis in February said it would convert manufacturing operations in Stein, Switzerland, into a life sciences hub focused on cell and gene therapy production. (Novartis) Like many CDMOs these days, Switzerland s Celonic aims to make a big splash in cell and gene therapy and it s picked up space at an emerging Novartis life sciences hub to take that work to the next level. Celonic sewed up a long-term lease for production and office space in the WST-222 building of Novartis’ hub-to-be in Stein, Switzerland, dubbed Life Science Park Rheintal. The company will use the 91,500-square-foot location to set up production capacity for cell and gene therapies, next-generation vaccines and “innovative biopharmaceuticals.”

Switzerland generalKonstantin matentzogluLife science parkUncover rare disease insightsAccelerate commercializationImprove patientCell therapyCell therapy manufacturingGene therapyManufacturing plantசுவிட்சர்லாந்து ஜநரல்வாழ்க்கை அறிவியல் பூங்காவிரைவுபடுத்து வணிகமயமாக்கல்மேம்படுத்த நோயாளிசெல் சிகிச்சைசெல் சிகிச்சை உற்பத்தி

AbbVie sells biologics plant to Pharmaron, fueling the China company s cell and gene therapy ambitions

AbbVie sells biologics plant to Pharmaron, fueling the China company s cell and gene therapy ambitions
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoAllergan biologicsBoliang louEli lillyChina based pharmaronAbsorption systemsUncover rare disease insightsAccelerate commercializationImprove patientBig pharmaWestport campusCounty mayoஒன்றுபட்டது மாநிலங்களில்சான் டியாகோஒவ்வாமை உயிரியல்

Perrigo s generics split is back on the docket, thanks to $1 55B Altaris offer

Perrigo is selling its prescription generics business to Altaris Capital Partners for $1.55 billion. The generics unit, which recently nabbed approval for a copycat version of Teva's ProAir HFA inhaler, will establish itself as a standalone company, investment firm Altaris said. The deal is expected to close by the end of the third quarter.

Murray kesslerRosen katzGarikai nyaruwataGoldman sachsAltaris capital partnersUncover rare disease insightsAccelerate commercializationImprove patientTeva pharmaceuticalProair hfaM amp aMergers and acquisitionsTopical drug deliveryமுர்ரே கெஸ்லர்ரோஸன் க்யாட்ஸ்கோல்ட்மேன் சாக்ஸ்